Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Carcinoma

Carcinoma, Renal Cell

Kidney Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

DNA ploidy analysis

DNA stability analysis

chromosomal translocation analysis

cytogenetic analysis

flow cytometry

laboratory biomarker analysis

Robert P. Whitehead, MD

RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment.

PURPOSE: This laboratory study is analyzing the DNA in tumor tissue from patients with metastatic kidney cancer.

OBJECTIVES:

* Determine if cytogenetic abnormalities can predict clinical outcome, in terms of response to treatment and survival, in patients with metastatic renal cell carcinoma registered to the nephrectomy arm (arm I) of SWOG-8949.
* Correlate cytogenetic abnormalities and DNA content analysis (DNA index and S-phase fraction) with clinical outcome.

OUTLINE: This is a partially prospective, partially retrospective, multicenter, companion study.

Paraffin-embedded tumor tissue specimens from patients enrolled in SWOG-8949 are evaluated by cytogenetic analysis (e.g., presence of trisomy and loss of Y chromosome) and flow cytometric analysis (e.g., presence of nondiploid cells and presence of abnormal proliferation index).

PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study.

SWOG-9023, DNA Analysis of Tumor Tissue From Patients With Metastatic Kidney Cancer

Cytogenetic and Flow Cytometric Analysis of : Renal Cell Carcinoma: A Companion Protocol to SWOG-8949

Success is defined as obtaining at least 10 analyzable metaphases.

Abnormality is defined as at lease one clonal chromosomal abnormality.

National Cancer Institute (NCI)

SWOG Cancer Research Network

Symptoms and General Pathology

Blood and Lymph Conditions

Immune System Diseases

Recurrence

Leukemia

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Leukemia, Lymphoid

Neoplasm Metastasis

Leukemia, Myelomonocytic, Acute

Leukemia, Monocytic, Acute

Lymphoma

Hematologic Diseases

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Myeloid Leukemia

Acute Myeloid Leukemia

Acute Non Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Lymphoblastic Lymphoma

Acute Graft Versus Host Disease

Childhood Acute Lymphoblastic Leukemia

Acute Monoblastic Leukemia

Acute Myelomonocytic Leukemia

Lymphosarcoma

Completion of Telephone Study Entry Form, Additional On Study Form, and Specimen Transmittal Form.

Southern blotting

gene rearrangement analysis

mutation analysis

Beverly J. Lange, MD

Carolyn A. Felix, MD

RATIONALE: Studying samples of bone marrow and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This laboratory study is looking at DNA in bone marrow and blood samples from young patients with acute myeloid leukemia or acute lymphoblastic leukemia.

OBJECTIVES:

* Characterize the clinical, morphologic, immunologic, cytogenetic, and molecular heterogeneity of acute lymphoblastic leukemia or acute myeloid leukemia (AML) in infants and monoblastic variants of AML in young patients.
* Characterize the clinical, morphologic, immunologic, cytogenetic, and molecular heterogeneity of secondary AML in young patients.
* Compare secondary AML vs de novo AML at the level of Southern blot, breakpoint sequence, and DNA topoisomerase II cleavage sites.

OUTLINE: This is a multicenter study.

Bone marrow or blood are collected and analyzed by Southern blot for chromosome 11q23 breakpoints and translocations. Samples from patients with secondary acute myeloid leukemia are also examined for MLL gene rearrangements.

PROJECTED ACCRUAL: A total of 250 patients will be accrued for this study.

DNA Analysis of Bone Marrow and Blood Samples From Young Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

The Molecular Epidemiology of de Novo and Treatment Related 11q23 Leukemia in the Young

Children's Oncology Group

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
SWOG-9023, DNA Analysis of Tumor Tissue From Patients With Metastatic Kidney Cancer	NCT00900042	Kidney Cancer	DNA ploidy anal... DNA stability a... chromosomal tra... cytogenetic ana... flow cytometry laboratory biom...	-	SWOG Cancer Research Network
DNA Analysis of Bone Marrow and Blood Samples From Young Patients With Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	NCT00899652	Leukemia	Southern blotti... chromosomal tra... cytogenetic ana... gene rearrangem... mutation analys...	- 21 Years	Children's Oncology Group
SWOG-9023, DNA Analysis of Tumor Tissue From Patients With Metastatic Kidney Cancer	NCT00900042	Kidney Cancer	DNA ploidy anal... DNA stability a... chromosomal tra... cytogenetic ana... flow cytometry laboratory biom...	-	SWOG Cancer Research Network

Spots Global Cancer Trial Database for chromosomal translocation analysis